Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

<p>Abstract</p> <p>Background</p> <p>Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction. Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells and promote regulatory T-cell (...

Full description

Bibliographic Details
Main Authors:	Bonanno Giuseppina, Mariotti Andrea, Procoli Annabella, Folgiero Valentina, Natale Daniela, De Rosa Luca, Majolino Ignazio, Novarese Linda, Rocci Alberto, Gambella Manuela, Ciciarello Marilena, Scambia Giovanni, Palumbo Antonio, Locatelli Franco, De Cristofaro Raimondo, Rutella Sergio
Format:	Article
Language:	English
Published:	BMC 2012-12-01
Series:	Journal of Translational Medicine
Online Access:	http://www.translational-medicine.com/content/10/1/247

Similar Items

Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges.
by: Quan, J, et al.
Published: (2008)

Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges
by: Quan, J, et al.
Published: (2008)

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01)

Tolerance induction by monoclonal CD3 antibodies is dependent on indoleamine 2,3 dioxygenase (IDO)
by: Kuhn, C, et al.
Published: (2012)

Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
by: Lingfei Wu, et al.
Published: (2012-08-01)

The role of indoleamine 2,3-dioxygenase (IDO) in the pathogenesis of non-alcoholic steatohepatitis (NASH) and atherosclerosis as comorbidities
by: Arora, A, et al.
Published: (2021)

Indoleamine 2,3-Dioxygenase 1 (IDO1) in Kidney Transplantation: A Guardian against Rejection
by: Krzysztof Wiśnicki, et al.
Published: (2023-12-01)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
by: Ute F. Röhrig, et al.
Published: (2022-12-01)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
by: Ganiyu Olatunbosun Arinola, et al.
Published: (2023-01-01)

Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production
by: Michele Bellucci, et al.
Published: (2021-05-01)

Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience
by: Mee-seon Kim, et al.
Published: (2020-05-01)

Fatigue in Patients on Chronic Hemodialysis: The Role of Indoleamine 2,3-Dioxygenase (IDO) Activity, Interleukin-6, and Muscularity
by: Alessio Molfino, et al.
Published: (2023-02-01)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
by: Thiara Manuele Alves de Souza, et al.
Published: (2022-04-01)

Progesterone decreased indoleamine 2,3-dioxygenase 1(IDO1) expression in early pregnancy chorionic villi and decidua
by: Minyan Yang, et al.
Published: (2021-04-01)

Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
by: Hongchuan Zhao, et al.
Published: (2019-03-01)

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
by: Peng X, et al.
Published: (2022-08-01)

Rational design of indoleamine 2,3-dioxygenase inhibitors.
by: Röhrig, U, et al.
Published: (2010)

Identification of the first-in-class dual inhibitors of human DNA topoisomerase IIα and indoleamine-2,3-dioxygenase 1 (IDO 1) with strong anticancer properties
by: Barbara Kaproń, et al.
Published: (2023-12-01)

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
by: Jacques C. Mbongue, et al.
Published: (2015-09-01)

Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy
by: Gomes, B, et al.
Published: (2018)

Improved automated one-pot two-step radiosynthesis of (S)-[18F]FETrp, a radiotracer for PET imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
by: Aurélie Maisonial-Besset, et al.
Published: (2024-04-01)

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone
by: Yang Lin, et al.
Published: (2020-09-01)

First-in-Class, Thiosemicarbazide-Based, Dual Inhibitors of Human DNA Topoisomerase IIα and Indoleamine-2,3-Dioxygenase 1 (IDO-1) with Strong Anticancer Properties
by: Barbara Kaproń, et al.
Published: (2022-11-01)

Molecular mechanisms involved in the IL-6-mediated upregulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression in the chorionic villi and decidua of women in early pregnancy
by: Rui Wang, et al.
Published: (2022-12-01)

Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes.
by: Orabona, C, et al.
Published: (2018)

Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.
by: Larrea, E, et al.
Published: (2007)

Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta.
by: Kudo, Y, et al.
Published: (2004)

Decreased tryptophan catabolism by placental indoleamine 2,3-dioxygenase in preeclampsia.
by: Kudo, Y, et al.
Published: (2003)

The Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment
by: Xinting Huang, et al.
Published: (2022-06-01)

Local Inhibition of Indoleamine 2,3-Dioxygenase Mitigates Renal Fibrosis
by: Camilla Grønkjær Jensen, et al.
Published: (2021-07-01)

Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy
by: Bindu Singh, et al.
Published: (2023-01-01)

Comprehensive behavioral analysis of indoleamine 2,3‐dioxygenase knockout mice
by: Nao Hirata, et al.
Published: (2018-09-01)

Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma
by: Asim Farooq, et al.
Published: (2022-09-01)

Membrane Localization and Phosphorylation of Indoleamine 2,3-Dioxygenase 2 (IDO2) in A549 Human Lung Adenocarcinoma Cells: First Steps in Exploring Its Signaling Function
by: Chiara Suvieri, et al.
Published: (2023-11-01)

Effectiveness of Soluble CTLA-4-Fc in the Inhibition of Bone Marrow T-Cell Activation in Context of Indoleamine 2.3-Dioxygenase (IDO) and CD4+Foxp3+ Treg Induction
by: Massalska M, et al.
Published: (2022-12-01)

Indoleamine 2,3 dioxygenase activity aggravates the course and pathology of murine tuberculosis
by: Guo, L, et al.
Published: (2018)

Serum indoleamine 2,3-dioxygenase level and diagnostic value in patients with rosacea
by: Merve Sena Odabasi, et al.
Published: (2023-01-01)

Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources
by: Ying Tan, et al.
Published: (2022-11-01)